Detalhe da pesquisa
1.
Structure-based drug design of novel ASK1 inhibitors using an integrated lead optimization strategy.
Bioorg Med Chem Lett
; 27(8): 1709-1713, 2017 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28291695
2.
Synthetic Approaches to the New Drugs Approved During 2022.
J Med Chem
; 67(6): 4376-4418, 2024 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38488755
3.
Design and Discovery of a Potent and Selective Inhibitor of Integrin αvß1.
J Med Chem
; 2024 Jun 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38872300
4.
Synthetic Approaches to the New Drugs Approved During 2021.
J Med Chem
; 66(15): 10150-10201, 2023 08 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37528515
5.
Synthetic Approaches to the New Drugs Approved During 2020.
J Med Chem
; 65(14): 9607-9661, 2022 07 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35833579
6.
Prokinetic actions of luminally acting 5-HT4 receptor agonists.
Neurogastroenterol Motil
; 33(4): e14026, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33185015
7.
Synthetic Approaches to the New Drugs Approved during 2019.
J Med Chem
; 64(7): 3604-3657, 2021 04 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33783211
8.
Correction to "Structure-Based Design of ASK1 Inhibitors as Potential Agents for Heart Failure".
ACS Med Chem Lett
; 8(12): 1341, 2017 12 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-29259759
9.
Structure-Based Design of ASK1 Inhibitors as Potential Agents for Heart Failure.
ACS Med Chem Lett
; 8(3): 316-320, 2017 Mar 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28337323
10.
Hit-to-Lead Optimization and Discovery of 5-((5-([1,1'-Biphenyl]-4-yl)-6-chloro-1H-benzo[d]imidazol-2-yl)oxy)-2-methylbenzoic Acid (MK-3903): A Novel Class of Benzimidazole-Based Activators of AMP-Activated Protein Kinase.
J Med Chem
; 60(21): 9040-9052, 2017 11 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29035567
11.
Copper catalysed aerobic oxidation of benzylic alcohols in an imidazole containing N4 ligand framework.
Dalton Trans
; 45(45): 18356-18364, 2016 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27808292
12.
Optometry's role in managing patients with glaucoma.
Clin Exp Optom
; 99(1): 1-3, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26875848
13.
Discovery of a series of phosphonic acid-containing thiazoles and orally bioavailable diamide prodrugs that lower glucose in diabetic animals through inhibition of fructose-1,6-bisphosphatase.
J Med Chem
; 54(1): 153-65, 2011 Jan 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-21126019
14.
Fructose-1,6-bisphosphatase Inhibitors. 2. Design, synthesis, and structure-activity relationship of a series of phosphonic acid containing benzimidazoles that function as 5'-adenosinemonophosphate (AMP) mimics.
J Med Chem
; 53(1): 441-51, 2010 Jan 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-20055427
15.
Novel, potent non-covalent thrombin inhibitors incorporating p(3)-lactam scaffolds.
Bioorg Med Chem Lett
; 12(5): 743-8, 2002 Mar 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-11858993
16.
Non-covalent thrombin inhibitors featuring P(3)-heterocycles with P(1)-monocyclic arginine surrogates.
Bioorg Med Chem Lett
; 12(8): 1203-8, 2002 Apr 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-11934589
17.
Non-covalent thrombin inhibitors featuring P3-heterocycles with P1-bicyclic arginine surrogates.
Bioorg Med Chem Lett
; 12(20): 2925-30, 2002 Oct 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-12270176